Crmo Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
- Paid Up Capital ₹ 0.94 M
- Company Age 21 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.50 Cr
- Revenue Growth 454.07%
- Profit Growth 414.07%
- Ebitda 6515.88%
- Net Worth 20.69%
- Total Assets 87.12%
About Crmo Pharmatech
Crmo Pharmatech Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 May 2003 and has a history of 21 years and nine months. Its registered office is in Gandhi Nagar, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 0.94 M.
The company has closed loans amounting to ₹1.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Parul Oza and Nalini Oza serve as directors at the Company.
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ2003PTC042350
- Company No.
042350
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 May 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Crmo Pharmatech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nalini Oza  | Director | 06-May-2003 | Current |
| Parul Oza | Director | 06-May-2003 | Current |
Financial Performance of Crmo Pharmatech.
Crmo Pharmatech Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 454.07% increase. The company also saw a substantial improvement in profitability, with a 414.07% increase in profit. The company's net worth Soared by an impressive increase of 20.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Crmo Pharmatech?
In 2017, Crmo Pharmatech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmalinkage LlpParul Oza and Nalini Oza are mutual person
Charges (Loans)
₹0
₹15.00 M
Charges Breakdown by Lending Institutions
- 3I Infotech Trusteeship Services Limited : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Apr 2008 | 3I Infotech Trusteeship Services Limited | ₹1.50 Cr | Satisfied |
How Many Employees Work at Crmo Pharmatech?
Unlock and access historical data on people associated with Crmo Pharmatech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Crmo Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crmo Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.